NRAW have a look at the revenue growth of AVH it is basically a year behind PNV...... Management expects revenue of around $78,000,000 and cashflow break even by second quarter 2025. Combining the two makes heaps of sense and synergies as both have large USA based sales forces.
Time will tell i just wanted to let people know and have a look at AVH, I've done very well out of PNV and learned loads from some clever PNV posters so wanted to pay a bit back.
The increase in joint studies of BTM and Recall will only get more and more in my opinion and the AVH share price is very attractive coming from a PNV script prospective and both have nil debt
The Clinicians Speak, page-1012
-
- There are more pages in this discussion • 40 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PNV (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.58 |
Change
0.040(1.57%) |
Mkt cap ! $1.781B | |||
| Open | High | Low | Value | Volume |
| $2.56 | $2.59 | $2.53 | $3.881M | 1.517M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 10150 | $2.57 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.58 | 38947 | 2 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| PNV (ASX) Chart |